Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAniracetam
Description: Inhibits desensitization; AMPA > kainate
Chemical Name: 1-(4-Methoxybenzoyl)-2-pyrrolidinone
Purity: ≥99% (HPLC)
Biological Activity for Aniracetam
Aniracetam is a nootropic, with modulatory actions through allosteric potentiation of AMPA specific receptors, reduction of glutamate receptor desensitization and potentiation of metabotropic glutamate receptor activity. Anxiolytic following systemic administration.
Technical Data for Aniracetam
| M. Wt | 219.24 |
| Formula | C12H13NO3 |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 72432-10-1 |
| PubChem ID | 2196 |
| InChI Key | ZXNRTKGTQJPIJK-UHFFFAOYSA-N |
| Smiles | COC1=CC=C(C=C1)C(=O)N1CCCC1=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Aniracetam
References for Aniracetam
References are publications that support the biological activity of the product.
Isaacson and Nicholl (1991) Aniracetam reduces glutamate receptor desensitisation and slows the decay of fast excitatory synaptic currents in the hippocampus. Proc.Natl.Acad.Sci.U.S.A. 88 10936 PMID: 1660156
Ito et al (1990) Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J.Physiol. 424 553 PMID: 1975272
Nakamura and Kurasawa (2001) Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur.J.Pharmacol. 420 33 PMID: 11412837
View Related Products by Target
View Related Products by Product Action
Keywords: Aniracetam, Aniracetam supplier, Desensitization, inhibitors, inhibits, AMPA, kainate, Glutamate, Receptors, iGluR, Ionotropic, allosteric, modulators, potentiators, 0867, Tocris Bioscience
1 Citation for Aniracetam
Citations are publications that use Tocris products. Selected citations for Aniracetam include:
Moldavan and Allen (2010) Retinohypothalamic tract synapses in the rat suprachiasmatic nucleus demonstrate short-term synaptic plasticity. J Neurophysiol 103 2390 PMID: 20220078
Reviews for Aniracetam
There are currently no reviews for this product. Be the first to review Aniracetam and earn rewards!
Have you used Aniracetam?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.